Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd. - American Depositary Shares
(NQ:
CMMB
)
1.930
+0.130 (+7.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
137,595
Open
1.880
Bid (Size)
1.850 (1,000)
Ask (Size)
1.930 (100)
Prev. Close
1.800
Today's Range
1.830 - 2.035
52wk Range
1.350 - 4.120
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
July 09, 2026
Via
Chartmill
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
July 08, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Performance
YTD
+7.8%
+7.8%
1 Month
+5.5%
+5.5%
3 Month
+5.5%
+5.5%
6 Month
+19.1%
+19.1%
1 Year
-50.3%
-50.3%
More News
Read More
11 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 02, 2026
Via
Benzinga
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
March 19, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
December 02, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
November 24, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
November 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 19, 2025
Via
Benzinga
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
June 30, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
June 11, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
June 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
May 05, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
April 28, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
April 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Medical and Clinical Appointments
April 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
↗
March 27, 2025
Via
Benzinga
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
March 27, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 25, 2025
Via
Benzinga
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
March 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Frequently Asked Questions
Is Chemomab Therapeutics Ltd. - American Depositary Shares publicly traded?
Yes, Chemomab Therapeutics Ltd. - American Depositary Shares is publicly traded.
What exchange does Chemomab Therapeutics Ltd. - American Depositary Shares trade on?
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares?
The ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares is CMMB on the Nasdaq Stock Market
What is the current price of Chemomab Therapeutics Ltd. - American Depositary Shares?
The current price of Chemomab Therapeutics Ltd. - American Depositary Shares is 1.930
When was Chemomab Therapeutics Ltd. - American Depositary Shares last traded?
The last trade of Chemomab Therapeutics Ltd. - American Depositary Shares was at 08/07/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
